Shanghai, China, and Singapore, November 16, 2026
Delonix Bioworks, a clinical-stage biotechnology company developing next-generation bacterial vaccines, has announced a research collaboration with ASTAR Infectious Diseases Labs (ASTAR IDL) to advance the development of novel engineered outer membrane vesicle (OMV) vaccine candidates targeting Klebsiella pneumoniae. The partnership brings together Delonix’s proprietary bacterial genome-editing technology and OMV Plusâ„¢ platform with A*STAR IDL’s expertise in translational infectious disease research, clinical bacterial isolates, and immunological evaluation. The collaboration aims to discover and evaluate innovative vaccine candidates that could address the growing threat of antimicrobial-resistant bacterial infections. The announcement represents an important development in vaccine research, particularly as healthcare systems worldwide face increasing challenges associated with multidrug-resistant pathogens. Through this collaboration, the organizations intend to investigate new preventive approaches against K. pneumoniae, a bacterium responsible for severe infections, including pneumonia, bloodstream infections, and sepsis. The research will focus on engineered bacterial vaccine technology designed to improve antigen presentation, immunogenicity, and the potential for protection across different bacterial strains.
Engineered OMV Technology Targets Drug-Resistant Bacteria
A central component of the collaboration is Delonix’s proprietary Outer Membrane Vesicle (OMV) Plusâ„¢ technology, which uses engineered bacterial vesicles as a platform for vaccine development. OMVs are naturally released, nanoscale structures derived from the outer membrane of Gram-negative bacteria. They contain bacterial components that can interact with the immune system and stimulate immune responses. By engineering these vesicles, researchers aim to develop vaccine candidates that present important bacterial antigens while addressing certain limitations associated with conventional vaccine approaches. According to Delonix, its proprietary pathogenic bacterial genome-editing platform enables precise modifications intended to improve the characteristics of engineered OMVs. These modifications include modulating capsular interference, detoxifying endotoxins, and enriching conserved native antigens on non-replicating vesicles. The objective is to improve antigen accessibility and potentially stimulate both innate and adaptive immune responses. The technology is particularly relevant to K. pneumoniae, which exhibits considerable genetic diversity and possesses thick capsular polysaccharides that can conceal important surface antigens. These characteristics have complicated the development of broadly protective vaccines. By investigating engineered OMVs, the collaboration aims to explore an alternative strategy for addressing these biological challenges and developing candidates with potential activity against multiple bacterial strains.
Addressing the Growing Threat of Klebsiella pneumoniae
Klebsiella pneumoniae represents a significant global public health challenge because it can cause serious infections, particularly among hospitalized patients and individuals with weakened immune systems. The bacterium is associated with pneumonia, bloodstream infections, urinary tract infections, and sepsis. The emergence and spread of antimicrobial-resistant strains have further complicated treatment, reducing the effectiveness of commonly used antibiotics. The World Health Organization has identified carbapenem-resistant Enterobacterales, including K. pneumoniae, among its critical-priority bacterial threats. Despite the considerable disease burden, there are currently no licensed vaccines specifically available to prevent K. pneumoniae infections. Conventional vaccine development has faced challenges because of variations in bacterial surface structures, different capsular types, and the ability of the pathogen to evade immune recognition. The Delonix–ASTAR collaboration aims to address these challenges by combining bacterial genome engineering with advanced immunological research. ASTAR IDL will contribute its capabilities in evaluating clinically relevant bacterial isolates and studying immune responses. The partners plan to generate and assess vaccine candidates for safety, immunogenicity, and broad cross-strain protective potential, supporting research into preventive strategies against drug-resistant infections.
Collaboration Strengthens Next-Generation Vaccine Development
The partnership forms part of Delonix Bioworks’ broader strategy to expand its global research network and accelerate the development of genetically engineered bacterial vaccines. The company is advancing a pipeline that includes candidates targeting meningococcal group B, pertussis, gonorrhoea, and K. pneumoniae infections. Its lead candidate, DX-104, is currently undergoing Phase I clinical trials in Australia and China. The collaboration with ASTAR IDL provides an opportunity to combine proprietary vaccine engineering technologies with specialized infectious disease research capabilities in Singapore. For ASTAR, the partnership also supports efforts to translate laboratory research into potential interventions against antimicrobial-resistant pathogens. The collaboration highlights the growing importance of biotechnology partnerships in developing innovative vaccines against difficult-to-treat bacterial infections. Further research will be required to establish the safety, immunogenicity, and protective effectiveness of the engineered OMV candidates before any potential clinical application. Nevertheless, the initiative represents a promising research direction in next-generation bacterial vaccine development and the global effort to address antimicrobial resistance.
Source: Delonix Bioworks press release



